Autocrine, paracrine, and juxtacrine are recognized modes of action for mammalian EGFR ligands including EGF, TGF-a (TGFa), amphiregulin (AREG), heparin-binding EGFlike growth factor (HB-EGF), betacellulin, epiregulin, and epigen. We identify a new mode of EGFR ligand signaling via exosomes. Human breast and colorectal cancer cells release exosomes containing full-length, signaling-competent EGFR ligands. Exosomes isolated from MDCK cells expressing individual full-length EGFR ligands displayed differential activities; AREG exosomes increased invasiveness of recipient breast cancer cells 4-fold over TGFa or HB-EGF exosomes and 5-fold over equivalent amounts of recombinant AREG. Exosomal AREG displayed significantly greater membrane stability than TGFa or HB-EGF. An average of 24 AREG molecules are packaged within an individual exosome, and AREG exosomes are rapidly internalized by recipient cells. Whether the composition and behavior of exosomes differ between nontransformed and transformed cells is unknown. Exosomes from DLD-1 colon cancer cells with a mutant KRAS allele exhibited both higher AREG levels and greater invasive potential than exosomes from isogenically matched, nontransformed cells in which mutant KRAS was eliminated by homologous recombination. We speculate that EGFR ligand signaling via exosomes might contribute to diverse cancer phenomena such as field effect and priming of the metastatic niche.
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Results and Discussion
EGFR Ligands Are Present in Exosomes EGFR ligands are produced as type 1 transmembrane proteins [1] . How they are trafficked, processed, and released determine the range, amplitude, and duration of downstream EGFR signaling [2] . This study was spurred by our detection of full-length HB-EGF in the conditioned medium of MDA-MB-231 breast cancer cells without its presence at the plasma membrane (PM) (not shown). EGFR ligands act as soluble autocrine and paracrine factors or in a juxtacrine manner as full-length, uncleaved, cell surface ligands [3, 4] . However, we hypothesized that extracellular release of HB-EGF in exosomes might explain this observation. Exosomes are 30-100 nm extracellular nanovesicles produced by intralumenal budding of multivesicular bodies (MVB) and MVB-PM fusion [5] . We purified <200-nm-sized extracellular vesicles that were from MDA-MB-231 cell conditioned medium by sucrose gradient fractionation (Experimental Procedures). These fractions were immunoblotted; fractions 4-6 contained peak levels of HB-EGF and exosomal proteins CD9, ADAM-10, and ADAM-17 [6, 7] but were negative for the ER marker calreticulin ( Figure 1A ). Transmission electron microscopy (TEM) of fractions 4-6 showed 30-50 nm vesicles with morphological characteristics of exosomes ( Figure S1A ) [5] .
To determine whether other EGFR ligands were localized in these extracellular vesicles, we utilized fluorescence-activated vesicle sorting (FAVS). We developed this approach to isolate small (<100 nm) vesicles [8] and to perform vesicleby-vesicle analysis and thus avoid signal loss due to bulk measurements and signal averaging. HB-EGF and TGFa were detected in extracellular vesicles purified from MDA-MB-231 cells and HCA-7 colorectal cancer cells, whereas AREG was detected only in HCA-7 vesicles ( Figure 1B ; see also Figure S1B ). These results provide the first evidence that EGFR ligands are released in extracellular vesicles.
To be more confident that EGFR ligand-containing extracellular vesicles are exosomes, we immunoblotted whole-cell lysates (WCL) or vesicle preparations from the conditioned medium of MDCK cells stably expressing AREG (MDCK AREG) for AREG, exosomal markers (Hsp-70 [9] [10] [11] , Tsg101 [12, 13] , and flotillin-1 [14] [15] [16] ), nuclear markers (lamin A/C and poly [ADP-ribose] polymerase [PARP]), the ER marker (calreticulin), and the mitochondrial marker (voltage-dependent anion channel [VDAC] ). The vesicle preparations contained exosomal markers but not the other organelle markers ( Figure S1C ), indicating that these vesicles are likely exosomes. Furthermore, the calculated mean diameter from three independent sets of vesicles from the conditioned medium of MDCK AREG cells was 51.3 nm ( Figure 1C ), a size previously described as characteristic of exosomes [5] . We detected only scattered vesicles larger than 100 nm and little cellular debris. We cannot exclude the possibility that our extracellular-vesicle preparations also contain shedding vesicles. However, shed vesicles are classically defined as up to 1 mm in diameter; smaller shedding vesicles have been described, but they are typically not less than 100-200 nm [17] . Therefore, on the basis of their size ( Figure 1C ; see also Figure S1A ) and composition ( Figure 1A ; see also Figure S1C ), our vesicle preparations appear to be highly enriched for exosomes.
Utilizing FAVS, we tested whether exosomal EGFR ligands were full-length and displayed in a proper orientation to engage receptors on recipient cells. Using N-or C-terminusspecific antibodies, we found the N terminus of endogenous TGFa on the outside of MDA-MB-231 exosomes. Likewise, heterologous AREG (both wild-type AREG and C-terminally HA-tagged AREG expressed in MDCK cells) exhibited the same exosomal topology as TGFa ( Figure 1D ). These results demonstrate that exosomal TGFa and AREG are in a signaling-competent orientation such that the N terminus is available to engage recipient cell EGFR.
AREG-Containing Exosomes Induce Recipient Cell Invasion
To examine the function of individual EGFR ligands, we purified exosomes from parental MDCK cells expressing undetectable levels of EGFR ligands [18] and MDCK cells overexpressing HB-EGF, TGFa, or AREG. As a functional readout of exosome activity, we assessed the effect of exosomes on recipient cancer cell invasion, a hallmark of malignancy. Using a modified Boyden chamber assay, we found that AREG exosomes stimulated similar levels of invasion for MDA-MB-231-derived LM2-4175 and LMO-1833 recipient cells that metastasize to lung and bone, respectively [19] ; results from LM2-4175 cells are shown. We determined that exosomes purified from the conditioned medium of MDCK cells overnight or after a 2 hr exposure to ionomycin exhibited identical invasive effects; thus, these two preparations were pooled in all subsequent experiments ( Figure S2A ).
For the invasion assays, LM2-4175 cells were treated with serum-free medium alone or with the following supplements: MDCK AREG WCL or parental, HB-EGF, TGFa, or AREG exosomes. Treatment-containing, serum-free medium was replaced every 24 hr, and the number of cells that invaded through Matrigel to the undersurface of Transwell filters was quantified after 72 hr. LM2-4175 cell invasion was not affected by serum-free medium, and increases in serum concentration increased invasion (not shown). AREG exosomes enhanced invasiveness of LM2-4175 cells 4-fold over TGFa or HB-EGF exosomes and 5-fold over parental MDCK exosomes or MDCK AREG WCL (Figures 2A and 2B) . Two experiments performed in duplicate showed that the concentration per miligram of exosomal protein was 793.5 ng of AREG, 749 ng of TGFa, and 931.5 ng of HB-EGF, suggesting similar amounts of the ligands in MDCK cell exosomes. Thus, differences in exosomal ligand concentration cannot explain the greater invasive potential of AREG exosomes.
We next compared the invasive potential of AREG exosomes to that of recombinant ligands. ELISA showed that the concentration of AREG exosomes was 20 ng/ml (Experimental Procedures). At this concentration of exosomal AREG and recombinant ligands, AREG exosomes increased the number of invading LM2-4175 cells 5-fold more than recombinant ligands ( Figure 2C ). In a concentration-response experiment, 100 ng/ml recombinant AREG ( Figure S2B ) did not achieve the invasive effect of exosomes containing 20 ng/ml AREG ( Figures 2B and 2C) . In a separate experiment, AREG exosomes enhanced wound healing in comparison to serumfree control or recombinant AREG ( Figure S2C ). Combined, these results demonstrate that AREG exosomes impart greater recipient cell invasiveness than parental MDCK exosomes, exosomes containing other EGFR ligands, or recombinant EGFR ligands.
To address how much of the effect of AREG exosomes is due to AREG itself, we treated recombinant AREG or AREG exosomes with or without AREG-neutralizing antibody for 1 hr prior to incubation with LM2-4175 cells. Regardless of exosome concentration, AREG-neutralizing antibody reduced the number of invasive cells by approximately 50% (Figure 2D ). Because all known biological effects of AREG are mediated by EGFR binding, our results suggest the invasive effect of AREG exosomes is due, at least in part, to exosomal AREG activation of recipient cell EGFR. A similar effect was found when recipient LM2-4175 cells were treated for 1 hr prior to AREG exosome incubation with an EGFR-neutralizing monoclonal antibody (mAb 528) (not shown), which also decreases exosomal internalization (see below).
Exosomal AREG stability and packaging To begin addressing why AREG exosomes impart enhanced invasiveness compared to TGFa or HB-EGF exosomes, we tested the stability of exosomal EGFR ligands. Baseline levels of exosomal membrane-bound ligands were determined by ELISA. Exosomes were incubated in the presence or absence of the metalloprotease inhibitor galardin for 1 and 24 hr [20] ; ligand concentrations were again determined, and the results were expressed as the percent of exosomal ligand compared to the baseline. There is little difference in the percent of exosomal AREG at one or 24 hr compared to TGFa or HB-EGF (Table S1 ), suggesting AREG exhibits greater membrane stability in exosomes than TGFa or HB-EGF, likely due to its resistance to membrane cleavage despite the presence of mature, active ADAM-10 and ADAM-17 in exosomes ( Figure 1A and [6] ).
We utilized quantitative confocal microscopy to determine how many molecules of AREG are present in a single exosome. Fluorescent intensity of individual exosomes purified from MDCK cells stably expressing EGFP-tagged AREG (AREG-EGFP exosomes) was correlated to the number of AREG-EGFP molecules by comparison to known concentrations of purified EGFP protein. A histogram of the AREG-EGFP molecules per exosome shows an average of 24 AREG-EGFP molecules (24.0 6 7.6) present in an individual exosome ( Figure 3A) . We speculate that both the relative membrane stability and compact packaging within exosomes contribute to the enhanced invasive effect of AREG exosomes.
AREG Exosomes Are Rapidly Internalized
To begin characterizing the interaction of exosomes with recipient cells, we tested whether LM2-4175 cells internalize AREG exosomes. LM2-4175 cells were incubated for 1-60 min with AREG exosomes stained with DiD, a fluorescent, lipophilic, membrane-diffuse dye. By flow cytometry, we determined the initial recipient cell mean DiD fluorescent intensity. We then incubated cells with Sudan Black to quench surfacebound DiD, and we repeated flow cytometry to quantitate the percent of cells with internalized DiD-stained exosomes. The majority of cells internalized exosomes by 10 min, indicating rapid uptake ( Figure 3B ). At this time point, recipient cell pretreatment with the EGFR mAb 528 resulted in a 50% decrease in the percent of internalized DiD-stained exosomes (percent quenched of total mean intensity) ( Figure 3E ), suggesting AREG exosome internalization is mediated, at least in part, by recipient cell EGFR.
To substantiate exosome internalization by recipient cells, we coincubated DiD-stained AREG exosomes or AREG-EGFP exosomes with LM2-4175 cells for 30 min, stained the plasma membrane with concanavalin A (ConA), and viewed internalization by confocal microscopy. The results suggest that AREG exosomes are internalized as indicated by the intracellular punctate, vesicle-like structures in the xy (Figures 3C and 3D ) and xz ( Figure 3D ; Movie S1 and Movie S2) planes. Thus, visualization of exosomal membranes and epitope-tagged AREG demonstrates internalization of AREG exosomes.
Mutant KRAS Status Correlates with Exosomal AREG Levels and Invasive Potential
Exosomes are detected in the serum of cancer patients [5, 10] ; however, it is unknown whether differences in the composition and behavior of exosomes exist between normal and transformed cells. To test this, we examined the composition of exosomes from a colorectal cancer cell line, DLD-1, containing one wild-type and one mutant activated KRAS allele and its isogenic derivatives in which the mutant allele (DKs-8) or wild-type allele (DKO-1) was eliminated by homologous recombination [21] . In contrast to their transformed counterparts, DKs-8 cells do not grow in soft agar or form tumors in nude mice. The EGFR ligand composition of DLD-1 cell exosomes was examined by FAVS; 42% stained individually for TGFa, 58.5% stained for HB-EGF, and 84.3% stained for AREG, whereas 28.5% of exosomes contained all three ligands (Table  S2 ). These results suggest that different exosome populations in these cells contain varying amounts of EGFR ligands.
We next determined how much AREG was in exosomes and WCL from DLD-1, DKO-1, and DKs-8 cells. Figure 4A shows a higher concentration of AREG in exosomes than in WCL in DLD-1 cells and its isogenic variants. Furthermore, there is an enrichment of AREG in the exosomes of cells with a mutant KRAS allele (DLD-1 and DKO-1). AREG immunoblotting of exosomes and WCL ( Figure 4B ) correlated with the AREG ELISA results ( Figure 4A ). The more slowly migrating bands above the 55 KDa AREG isoform in DKO-1 and DLD-1 exosomes might represent a post-translational modification (Figure 4B) , but future studies are needed to substantiate this possibility.
We next addressed whether the status of donor cell lines with regard to the KRAS mutant allele correlates with exosome-induced invasiveness of recipient cells. Figure 4C shows a correlation between levels of exosomal AREG and the ability to enhance invasion of recipient cells. Together, these data show that AREG is enriched in exosomes from mutant KRAS cells and that these exosomes increase recipient cancer cell invasion, supporting previous reports implicating a possible role for wild-type KRAS as a tumor suppressor [22, 23] .
In summary, we show that multiple cell lines produce exosomes containing EGFR ligands displayed in a signalingcompetent orientation. AREG exosomes enhance invasion of recipient cells in comparison to TGFa and HB-EGF exosomes and equivalent amounts of recombinant AREG. A single exosome contains an average of 24 membrane-stable AREG molecules, and AREG exosomes are rapidly internalized by recipient cells, which is at least partly dependent on AREG-EGFR binding. We postulate that exosomes are multivalent EGFR ligand signaling platforms, whereby exosomal packaging acts to concentrate AREG in a manner allowing aggregation and oligomerization of recipient cell EGFR during ligand engagement. We propose ExTRAcrine (exosomal targeted receptor activation) as a new mode of EGFR ligand signaling that might act in local or distant environments (see below). In addition, we show that isogenically matched nontransformed and transformed cells differ in the composition and behavior of their exosomes; mutant KRAS status correlates with increased exosomal AREG levels and invasiveness of recipient cells.
These results raise intriguing possibilities about the role(s) of exosomes in cancer. Cancer cell exosomes might act locally and contribute to the well-recognized, but poorly understood, cancer field effect [24, 25] . In addition, exosomes secreted by tumor cells might enter the bloodstream and deposit in distant sites, providing a hospitable environment (''priming the metastatic niche'') in which circulating EGFR-overexpressing tumor cells can lodge [26, 27] . Future studies will test these and other possibilities, including additional biological effects of exosomes and the attendant signaling cascades they initiate.
Experimental Procedures
Reagents and Antibodies All cell culture reagents were from HyClone (Logan, UT) unless otherwise stated. Fluorescent probes, including propidium iodide (PI), 1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethyl-indodi-carbocyanine perchlorate (DiD), and all secondary antibodies used in FAVS were purchased from Invitrogen-Molecular Probes (E) LM2-4175 cells were pretreated in the presence (EGFR mAb) or absence (CTL) of 20 mg/ml EGFR mAb 528 for 1 hr and then incubated with DiD-stained AREG exosomes for 10 min. Flow-cytometric analysis was performed as described in the Experimental Procedures. Data represent the mean 6 SD, p < 0.0001 (*).
(Carlsbad, CA). The AREG ectodomain antibody 6R1C2.4 [28, 29] was obtained from Bristol Myers Squib (Seattle, WA). The TGFa cytoplasmic tail antibody was made in collaboration with Covance (Princeton, NJ), and the TGFa ectodomain antibody was made in collaboration with East Acres Biologicals (Southbridge, MA) [30, 31] . The mouse HB-EGF antibody (MAB259) was purchased from R&D Systems (Minneapolis, MN) . Dr. Hideo Masui (Memorial SloanKettering Cancer Center) generously provided the EGFR mouse monoclonal antibody 528. The human AREG-, TGFa-and HB-EGF-specific sandwich ELISA kits were purchased from R&D Systems. Polyclonal antibodies to ADAM-10 and ADAM-17 were purchased from Millipore (Billerica, MA). Mouse monoclonal antibodies to Hsp70, lamin A/C, and CD9, rabbit polyclonal antibody to PARP, and goat polyclonal antibody to calreticulin were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). The rabbit polyclonal antibody to VDAC was purchased from Abcam (Cambridge, MA). The mouse (C) LM2-4175 cells were incubated for 2 hr with serum-free medium containing 20 ng/ml exogenous (recombinant human) AREG or 100 mg of the indicated exosomes, and the previously described invasion assay was performed. Data represent the mean 6 SD, p < 0.001 (*). monoclonal antibodies to Tsg101 and flotillin-1 were obtained from BD Biosciences (San Jose, CA). All other chemicals and antibodies were purchased from Sigma (St. Louis, MO).
Isolation of Exosomes
Native and elicited exosome pellets were pooled and subjected to sucrosegradient fractionation or differential centrifugation as described in the Supplemental Experimental Procedures.
Electron Microscopy
See Supplemental Experimental Procedures.
Biochemical Analysis
For immunoblotting, SDS-PAGE under reducing conditions was used for all blots except for AREG blots, which were separated under nonreducing conditions. Standard conditions were used for electrotransfer of samples to nitrocellulose or PVDF Immobilon membranes, and blots were blocked with non-fat milk or BSA in TBS-T according to the manufacturer's instructions. Blots were probed with the indicated antibodies.
Fluorescence-Activated Vesicle Sorting (FAVS)
FAVS analysis was performed as previously described [8, 32] . For a more detailed description, see Supplemental Experimental Procedures.
Invasion Assay LM2-4175 cells were cultured in complete DMEM supplemented with 10% bovine growth serum to 70% confluence, washed three times with PBS, and then maintained overnight in serum-free DMEM. Invasion was assessed by a modified Boyden chamber assay and a modified wound-healing assay (detailed in Supplemental Experimental Procedures).
Quantitative Assay of EGFP Molecules
For quantification of the number of AREG-EGFP molecules per exosome, 4 ml of a purified exosome suspension was sandwiched between a glass slide and a poly-L-lysine-coated 22 mm square coverslip. The poly-L-lysine coating was used for exosome immobilization. For further details on image capture and processing, see Supplemental Experimental Procedures.
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